From: Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy
Author (study) [ref.] | Pts (no.) | Cancer (type) | Chemotherapy (emetogenicity) | Antiemetics | HRQL assessment (times) | Selection of pts |
---|---|---|---|---|---|---|
Soukop (DB) [17] | 184 | Breast | Moderately | DEX + OND vs DEX + MTC | RSCL (before and after 6 days) | 187 pts eligible, 184 evaluated HRQL, 2 questions excluded (> 5% of pts no response) |
Clavel (DB) [19] | 252 | Breast | Moderately (FAC, FEC) | OND vs ALI | FLIC, FLIE (before and after 4 days) | 259 pts eligible, 252 evaluated HRQL with FLIC and 246 with FLIE |
Crucitt (DB) [20] | 113 | Breast LNH | Moderately | OND vs PCP | FLIC, FLIE (before and after 4 days) | 133 pts eligible, 113 evaluable for efficacy, 57 evaluated HRQL |
Lofters (DB) [21] | 696 | various | Moderately | OND ± DEX vs DOL ± DEX | EORTC QLQ-C30 (before and after 4 and 8 days) | 703 pts eligible, 696 evaluated HRQL |
Pater (DB) [22] | 402 | various | Moderately | DEX + OND or DOL vs DEX (delayed emesis) | EORTC QLQ-C30 (before and after 4 and 8 days) | 407 pts eligible, 402 evaluated HRQL |
Garbe (DB) [23] | 90 | Melan | Highly (dacarbazine) | TROP 5 mg vs TROP 10 mg | Mood, food intake, QL scales (before and after CT) | n.s. |
Barrenetxea (DB) [24] | 182 | Breast | Moderately (FAC, FEC) | OND for 3 days vs OND+MTC vs OND 1 dose | FLIC (before and for 5 days) | n.s. |
Lebeau (DB) [25] | 338 | various | Highly (cisplatin) | OND+MP vs OND+MP+ MTP | FLIC, FLIE (before and after 4 days) | n.s. |
Kobayashi (DB) [26] | 141 | various | Highly (cisplatin) | TROP vs PL (delayed emesis) | QOL-EVJ (before and daily for 30 days after) | 146 pts enrolled, 141 eligible, 98 evaluated HRQL |
Sorbe (R, O) [28] | 259 | various | Highly (cisplatin) | TROP vs MTC + DEX + LOR | 23 items (before and after 7 days) | n.s. |
Drechsler (R, O) [29] | 191 | various | Highly and Moderately | TROP vs TROP+DEX vs TROP+MTC | new scale (before and after CT) | n.s. |
Torok (R, O) [30] | 130 | Ovary | Highly (cisplatin) | OND vs GRAN vs MTC | RSCL (before and daily for 5 days) | n.s. |
Lachaine (O) [31] | 52 | Breast | Moderately | OND or MTC physician choice | EORTC QLQ-C30 (before and after 2 and 4 days) | 58 pts eligible, 52 evaluated HRQL |